title: Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure.
authors.affiliation: Department of Haematology, St James's University Hospital, Leeds, UK. richardkelly@nhs.net
authors.forename: R J
authors.initials: RJ
authors.lastname: Kelly
authors.forename: A
authors.initials: A
authors.lastname: Hill
authors.forename: L M
authors.initials: LM
authors.lastname: Arnold
authors.forename: G
authors.initials: G
authors.lastname: Khursigara
authors.forename: N S
authors.initials: NS
authors.lastname: Kanagasundaram
authors.forename: P
authors.initials: P
authors.lastname: Hillmen
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006457:Hemoglobinuria, Paroxysmal / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab